Results 231 to 240 of about 2,536 (255)

P0072 A local formulative approach changes the perspective of biotherapeutics administration

Journal of Crohn’s and Colitis
Abstract Background Although biologics have higher rates of remission compared to conventional therapies, systemic toxicity is often associated with biotherapeutics (1). Therefore, the protein’s side effects must be weighed against its potential benefits for treating colitis in patient ...
openaire   +1 more source

Comprehensive Stress Stability Studies Reveal the Prominent Stability of the Liquid-Formulated Biotherapeutic Asymmetric Monovalent Bispecific IgG1 Monoclonal Antibody Format

Journal of Pharmaceutical Sciences
The developed asymmetric monovalent bispecific IgG1 or Duet monoclonal antibody (Duet mAb) has two distinct fragment antigen-binding region (Fab) subunits that target two different epitope specificities sequentially or simultaneously. The design features include unique engineered disulfide bridges, knob-into-hole mutations, and kappa and lambda chains ...
Praveen Kallamvalliillam Sankaran, Ryte Poskute, Lydia Dewis, Yasunori Watanabe, Vanessa Wong, Laura Pascual Fernandez, Richard Shannon, Lisa Wong, Rebecca Shrubsall, Lee Carman, Alexander Holt, Giordana Lepore, Rahul Mishra, Laura Sewell, Matt Gothard, Matthew Cheeks, Viv Lindo   +16 more
openaire   +2 more sources

Formulation and device lifecycle management of biotherapeutics—decision architecture

2022
Beate Bittner, Johannes Schmidt
openaire   +1 more source

Shifting Perspectives on Biotherapeutic Treatment of Ulcerative Colitis using Lipid Mesophases: Formulation Design and Preclinical Validation

Abstract Biotherapeutics are required to achieve high remission rates in patients with severe ulcerative colitis (UC); however, adverse effects, complex dosing regimens, administration routes, and low patient compliance may limit their widespread clinical use.
Gazzi Rafaela, Cremona Tiziana, Czekalla Reto, Campbell Emily, Schwarzfischer Marlene, Rogler Gerhard, Scharl Michael, Bergadano Alessandra, Mezzenga Raffaele, Kuentz Martin, Luciani Paola, Aleandri Simone   +11 more
openaire   +1 more source

Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers

Cell Host and Microbe, 2022
Rajita Menon, Emily Crossette, Yun-Gi Kim   +2 more
exaly  

Formulation and Device Lifecycle Management of Biotherapeutics

2022
openaire   +1 more source

Treating Clostridioides difficile: Could Microbiota-based Live Biotherapeutic Products Provide the Answer?

Infection and Drug Resistance, 2023
Robert Orenstein, Do
exaly  

Formulation and device lifecycle management of biotherapeutics—leveraging synergies across therapeutic areas

2022
Beate Bittner, Johannes Schmidt
openaire   +1 more source

Discovery and delivery strategies for engineered live biotherapeutic products

Trends in Biotechnology, 2022
Nathan Crook, Aaron C Anselmo
exaly  

Enabling customer-centric and sustainable drug delivery— formulation and device lifecycle management of biotherapeutics

2022
Beate Bittner, Johannes Schmidt
openaire   +1 more source